CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 8 enrolled
Drug / intervention
Evacetrapib Tablet +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02271425
NCT02271425Phase 1Completed
CompareCT.gov

An Absolute Bioavailability Study of Evacetrapib in Healthy Subjects Using the Intravenous Tracer Method

Eli Lilly and Company·interventional·Posted Oct 22, 2014·Updated Mar 1, 2019

In Brief

A Phase 1 clinical trial evaluating Evacetrapib Tablet and Evacetrapib Intravenous for Healthy Volunteers. Completed, enrolled 8 participants across 1 site.

Detailed Summary

Evacetrapib (study drug) is an investigational drug being developed with the aim to help people at high risk of heart problems in the future. In this study we will be comparing how much of the study drug gets into the blood stream when it is given as a single dose (in tablet form) compared to an intravenous injection (given directly into a vein via a small needle). The study is expected to last at least 15 days for each participant, not including screening. Screening will occur up to 28 days before the study drug is given.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 22, 2014
Enrollment StartOct 1, 2014
Primary CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 11.7 years ago

Interventions

Evacetrapib Tabletdrug

Oral administration

Evacetrapib Intravenousdrug

Intravenous administration